CERN is publicly funded by its 23 Member States and Associate Member States. Find out below about how this investment creates a positive impact on society.
A team of experts from CERN shared their expertise on machine learning with Sanofi Pasteur, the vaccines business unit of Sanofi, a global life sciences company.
In March 2020, a working group was established by CERN Director-General Fabiola Gianotti as a response to the wealth of ideas and proposals put forward by the CERN community in contribution to the global fight against COVID-19
2019 saw the official launch of the Next Ion Medical Machine Study (NIMMS), an umbrella R&D programme for – both existing and new – CERN accelerator technologies linked to heavy-ion therapy.
Sharing software and codes in big data environments is a challenge. To do this efficiently researchers at CERN have developed a system called CernVM-FS, for CERN Virtual Machine File System, which is currently used in high-energy physics experiments to distribute about 350 million files.
CERN-MEDICIS (Medical Isotopes Collected from ISOLDE) is a unique facility designed to produce unconventional radioisotopes with the right properties to enhance the precision of both patient imaging and treatment.
The National Center for Oncological Hadrontherapy (CNAO) in Pavia, Italy, is a facility offering advanced therapy to fight cancer and one of only five centres in the world treating with both protons and carbon ions.
In 2020, CERN signed three new agreements with CNAO, the National Center for Oncological Hadrontherapy (Italy) and with EBG-MedAustron, the company responsible for the construction and operation of MedAustron cancer treatment and research centre (Austria).